The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial: can we deliver on its promise?

作者信息

O'Gara Patrick T

机构信息

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

出版信息

J Am Coll Cardiol. 2010 Mar 30;55(13):1359-61. doi: 10.1016/j.jacc.2009.11.061.

DOI:10.1016/j.jacc.2009.11.061

PMID:20338497

Abstract

摘要

相似文献

The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial: can we deliver on its promise?

J Am Coll Cardiol. 2010 Mar 30;55(13):1359-61. doi: 10.1016/j.jacc.2009.11.061.

Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.

J Am Coll Cardiol. 2010 Mar 30;55(13):1348-58. doi: 10.1016/j.jacc.2009.10.062.

Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.

J Am Coll Cardiol. 2009 Sep 29;54(14):1303-8. doi: 10.1016/j.jacc.2009.07.013.

Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.

Letter by Joshi regarding article, "Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy".

Circulation. 2008 Dec 16;118(25):e838; author reply e840-1. doi: 10.1161/CIRCULATIONAHA.108.780254.

Letter by Tarantini et al regarding article, "Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy".

Circulation. 2008 Dec 16;118(25):e839; author reply e840-1. doi: 10.1161/CIRCULATIONAHA.108.779082.

Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).

Am J Cardiol. 2009 Jul 1;104(1):1-4. doi: 10.1016/j.amjcard.2009.02.059. Epub 2009 Apr 16.

Is there an ischemic threshold beyond which percutaneous coronary intervention is beneficial in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial?

Am J Cardiol. 2007 Nov 1;100(9):1495. doi: 10.1016/j.amjcard.2007.05.045. Epub 2007 Jul 24.

Evolving concepts in selecting optimal strategies for the management of patients with stable coronary disease: pharmacologic or revascularization therapy.

Curr Opin Cardiol. 2009 Nov;24(6):591-5. doi: 10.1097/HCO.0b013e32833155e2.

Current analysis of the results of the COURAGE trial: has an optimal treatment been reached in clinical practice?

Am J Cardiovasc Drugs. 2009;9 Suppl 1:19-21. doi: 10.2165/1153165-S0-000000000-00000.

引用本文的文献

Clinical Updates in Coronary Artery Disease: A Comprehensive Review.

J Clin Med. 2024 Aug 6;13(16):4600. doi: 10.3390/jcm13164600.

Is There Still a Place for Revascularisation in the Management of Stable Coronary Artery Disease Following the ISCHEMIA Trial?

Heart Int. 2020 Aug 8;14(1):13-15. doi: 10.17925/HI.2020.14.1.13. eCollection 2020.

Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy.

Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202008. doi: 10.21542/gcsp.2020.8.

Chart review of acute myocardial infarction at a district hospital in KwaZulu-Natal, South Africa.

Afr J Prim Health Care Fam Med. 2016 Mar 30;8(1):e1-5. doi: 10.4102/phcfm.v8i1.1012.

Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):409-18. doi: 10.1161/CIRCOUTCOMES.113.000139. Epub 2013 Jul 9.

Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.

Vasc Health Risk Manag. 2010 Sep 7;6:749-74. doi: 10.2147/vhrm.s11100.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验